Nemaura Medical Inc (NMRD)

Etorro trading 970x250
Nemaura Medical Inc (NMRD) Logo

About Nemaura Medical Inc

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. Address: 57 West 57th Street, New York, NY, United States, 10019

Nemaura Medical Inc News and around…

Latest news about Nemaura Medical Inc (NMRD) common stock and company :

BioMedNewsBreaks – Why Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’
15 Oct, 2021 FinancialContent
Nemaura Medical Inc. Harnesses the Power of Patient-Provider Communication
06 Oct, 2021 Yahoo! Finance

NMRD has developed a proprietary technology that replaces traditional invasive methods of diagnosis and healthcare observation procedures Report notes that study participants are interested in using electronic methods to communicate more with their doctors between visits Better communication between patients and their healthcare providers impacts adherence to prescribed treatment According to a report published in Dove Medical Press, communication between patients and their physicians has a nota

Nemaura Medical Inc. (NASDAQ: NMRD) Harnesses the Power of Patient-Provider Communication
06 Oct, 2021 FinancialContent
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate at Upcoming LD Micro Main Event
05 Oct, 2021 FinancialContent
Nemaura Medical to Present at the LD Micro Main Event Conference
05 Oct, 2021 Yahoo! Finance

Loughborough, England, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that Chief Executive Officer Faz Chowdhury, Ph.D. will be presenting virtually at the 14th Annual LD Micro Main Event Conference. Dr. Chowdhury will deliver his corporate presentation on October 13 at 10:00 AM ET. Regist

Nemaura Medical Inc. Announces Beta Launch of MiBoKo
29 Sep, 2021 Yahoo! Finance

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application. According to the update, Nemaura’s Chief Executive Officer Dr. Faz Chowdhury will discuss MiBoKo in more detail during his corporate presentation sch

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Beta Launch of MiBoKo
29 Sep, 2021 FinancialContent
Nemaura Medical Launches Beta Version of Its Metabolic Health Program
29 Sep, 2021 FinancialContent
Nemaura Medical Inc. Reveals Attendance at This Year's H.C. Wainwright Global Investment Conference
28 Sep, 2021 Yahoo! Finance

Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021 Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025 Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on d

Nemaura Medical Inc. (NASDAQ: NMRD) Reveals Attendance at This Year’s H.C. Wainwright Global Investment Conference
27 Sep, 2021 FinancialContent
BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee
27 Sep, 2021 FinancialContent
Nemaura Medical Announces Commercial Agreement with UK Licensee
27 Sep, 2021 FinancialContent
NetworkNewsAudio – Nemaura Medical Inc. (NASDAQ: NMRD) Leading Out in Tech Solutions for Diabetes, Obesity
24 Sep, 2021 FinancialContent
Nemaura Medical Inc. (NASDAQ: NMRD) Diabetes, Obesity Solutions Differentiated in Form and Function
24 Sep, 2021 FinancialContent
Desperate for Solutions, Diabetes and Obesity Healthcare Sectors Find Answers, Hope in Innovative Tech
23 Sep, 2021 FinancialContent
Nemaura Medical Inc. (NASDAQ: NMRD) Offers Sought-After Solutions in Areas of Unmet Medical Need
22 Sep, 2021 FinancialContent
InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Present at Benzinga Healthcare Small Cap Conference
21 Sep, 2021 FinancialContent
Healthcare Technologies Spearheading Modern Medicine Movement, Providing Hope to Throttle Diabetes, Obesity
21 Sep, 2021 FinancialContent
Nemaura Medical to Present at the Benzinga Healthcare Small Cap Conference
21 Sep, 2021 FinancialContent
48 Biggest Movers From Yesterday
21 Sep, 2021 FinancialContent

Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 ...

35 Stocks Moving In Monday's Mid-Day Session
20 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. ...

Nemaura Medical Inc. Is 'One To Watch'
20 Sep, 2021 Yahoo! Finance

Nemaura’s flagship product, sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor (“CGM”) designed for people with diabetes and prediabetes sugarBEAT received CE mark clearance in May 2019, allowing it to be marketed and sold within the European Union, and Nemaura has submitted a premarket approval application to the U.S. FDA Nemaura continues to build a world-class management team Nemaura plans to launch a direct to consumer metabolic health program in 2021, using it

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names World-Renowned Thought Leader as Advisory Board Member
17 Sep, 2021 FinancialContent
Nemaura Medical Inc. (NASDAQ: NMRD) Is ‘One to Watch’
17 Sep, 2021 FinancialContent
Nemaura Medical announce Professor Osama Hamdy Joins their Advisory Board
17 Sep, 2021 FinancialContent
65 Biggest Movers From Yesterday
03 Sep, 2021 FinancialContent

Gainers AgileThought, Inc. (NASDAQ: AGIL) shares surged 69.4% to settle at $23.53 on Thursday. AgileThought 13D Filings from ...

Nemaura Medical to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
01 Sep, 2021 FinancialContent
Nemaura Medical Becomes Oversold (NMRD)
23 Aug, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Nemaura Medical Reports Financial Results and Provides Business Update for the First Fiscal Quarter Ended June 30, 2021
16 Aug, 2021 FinancialContent
Here's What Nemaura Medical Inc.'s (NASDAQ:NMRD) Shareholder Ownership Structure Looks Like
26 Jul, 2021 Yahoo! Finance

A look at the shareholders of Nemaura Medical Inc. ( NASDAQ:NMRD ) can tell us which group is most powerful...

Nemaura Medical Inc (NMRD) is a NASDAQ Common Stock listed in , ,

970x250